立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

003020 立方制药

交易中 03-19 09:42:18

{"stockData":{"symbol":"003020","market":"SZ","secType":"STK","nameCN":"立方制药","latestPrice":24.88,"timestamp":1773884538000,"preClose":24.77,"halted":0,"volume":494400,"delay":0,"changeRate":0.0044,"floatShares":138000000,"shares":190000000,"eps":0.8548,"marketStatus":"交易中","change":0.11,"latestTime":"03-19 09:42:18","open":24.57,"high":25.24,"low":24.56,"amount":12361100,"amplitude":0.0275,"askPrice":24.89,"askSize":15,"bidPrice":24.85,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.8548,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1773891000000},"marketStatusCode":2,"adr":0,"adjPreClose":24.77,"symbolType":"stock","openAndCloseTimeList":[[1773883800000,1773891000000],[1773896400000,1773903600000]],"highLimit":27.25,"lowLimit":22.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":190182182,"isCdr":false,"pbRate":2.62,"roa":"--","peRate":29.106224,"roe":"6.79%","epsLYR":0.84,"committee":-0.263158,"marketValue":4732000000,"turnoverRate":0.0036,"status":0,"floatMarketCap":3427000000},"requestUrl":"/m/hq/s/003020","defaultTab":"news","newsList":[{"id":"2620564269","title":"股市必读：3月18日立方制药发生1笔大宗交易 成交金额202.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620564269","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620564269?lang=zh_cn&edition=full","pubTime":"2026-03-19 02:26","pubTimestamp":1773858372,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，立方制药报收于24.77元，上涨1.81%，换手率0.79%，成交量1.09万手，成交额2677.07万元。交易信息汇总资金流向3月18日主力资金净流入109.6万元；游资资金净流入31.32万元；散户资金净流出140.92万元。大宗交易3月18日立方制药发生1笔大宗交易，成交金额202.27万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900001249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2620447677","title":"3月17日立方制药发生1笔大宗交易 成交金额221.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620447677","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620447677?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:58","pubTimestamp":1773737935,"startTime":"0","endTime":"0","summary":"证券之星消息，3月17日立方制药发生大宗交易，交易数据如下：大宗交易成交价格23.11元，相对当日收盘价折价5.01%，成交9.6万股，成交金额221.86万元，买方营业部为广发证券股份有限公司广州寺右新马路证券营业部，卖方营业部为民生证券股份有限公司安徽分公司。近三个月该股共发生1笔大宗交易，合计成交960.0手，折价成交1笔。截至2026年3月17日收盘，立方制药报收于24.33元，上涨0.0%，换手率0.93%，成交量1.28万手，成交额3134.72万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700028667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2618402306","title":"立方制药最新公告：益气和胃胶囊获批国家中药保护品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2618402306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618402306?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:00","pubTimestamp":1773054050,"startTime":"0","endTime":"0","summary":"立方制药(003020.SZ)公告称，公司益气和胃胶囊获批为国家中药二级保护品种，保护期限自公告日起七年。该药品为国家医保和国家基药独家品种，获得多个指南共识推荐，有利于提升公司产品的市场竞争力，对公司产品的知识产权保护起到积极的影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900027868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2616482356","title":"立方制药（003020）披露参加国家组织集采药品协议期满品种接续采购中选公告，3月2日股价下跌3.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616482356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616482356?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:14","pubTimestamp":1772464456,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，立方制药报收于24.75元，较前一交易日下跌3.17%，最新总市值为47.07亿元。近日，合肥立方制药股份有限公司披露《关于参加国家组织集采药品协议期满品种接续采购中选的公告》。2025年前三季度上述产品合计销售额为14,028万元，占公司同期营业收入的12.98%。医疗机构将优先使用中选药品并完成约定采购量，有利于提升公司市场占有率和品牌形象。最终采购量及合同签订存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2610649753","title":"立方制药最新公告：硝苯地平控释片等3个产品拟中选国家组织集采药品协议期满品种接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610649753?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:09","pubTimestamp":1770721773,"startTime":"0","endTime":"0","summary":"立方制药公告称，公司近日参加了国家组织集采药品协议期满品种接续采购的投标工作，硝苯地平控释片、盐酸文拉法辛缓释片、盐酸曲美他嗪缓释片拟中选。2025年前三季度，上述3个产品合计销售额为14,028万元，占公司2025年前三季度营业收入比例为12.98%。但拟中选结果尚需公示无异议后确认，供应地区和数量亦尚未确认，采购合同签订等后续事项存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000032830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2610694184","title":"立方制药(003020.SZ)非奈利酮原料药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610694184","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610694184?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:48","pubTimestamp":1770695305,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)公告，公司收到国家药品监督管理局下发的非奈利酮原料药上市申请《受理通知书》。非奈利酮是一种新型、非甾体类、选择性盐皮质激素受体拮抗剂(MRA)，其制剂用于与2型糖尿病相关的慢性肾病成人患者，可降低eGFR持续下降、终末期肾病的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"立方制药(003020.SZ)非奈利酮原料药上市申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2602723443","title":"立方制药（003020）披露全资子公司取得药品注册证书，1月9日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602723443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602723443?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:49","pubTimestamp":1767970152,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，立方制药报收于27.98元，较前一交易日上涨0.39%，最新总市值为53.21亿元。该股当日开盘27.77元，最高27.98元，最低27.32元，成交额达1.14亿元，换手率为3.0%。近日，合肥立方制药股份有限公司全资子公司合肥诚志生物制药有限公司收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠用于类风湿关节炎、骨性关节炎、术后镇痛等多种炎症和疼痛症状。此次获批将丰富公司产品线，提升市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900041400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2602732912","title":"立方制药(003020.SZ)子公司取得一项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2602732912","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602732912?lang=zh_cn&edition=full","pubTime":"2026-01-09 17:29","pubTimestamp":1767950951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)公告，公司全资子公司合肥诚志生物制药有限公司(“诚志生物”)收到国家药品监督管理局核准签发的洛索洛芬钠口服溶液《药品注册证书》。洛索洛芬钠是一种苯丙酸类非甾体抗炎药，具有较好的镇痛、消炎、解热作用，尤其是镇痛作用较强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"立方制药(003020.SZ)子公司取得一项药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2602456143","title":"爱朋医疗：与立方制药共建联合创新中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2602456143","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602456143?lang=zh_cn&edition=full","pubTime":"2026-01-09 11:33","pubTimestamp":1767929609,"startTime":"0","endTime":"0","summary":"ADHD的治疗以药物治疗、心理治疗和行为训练为主。立方制药的片仿制药“立优加”今年9月正式宣布上市，成为国内首个该品种仿制药。公司于2025年11月4日与立方制药签署了战略合作框架协议，将共建联合创新中心，联合开展AI、脑机接口与药物疗效评价研究。目前双方合作正在逐步推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900015031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300753","BK0251","BK0250","003020"],"gpt_icon":0},{"id":"2601892663","title":"立方制药（003020）新增【人脑工程】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892663?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:30","pubTimestamp":1767702620,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，1月6日立方制药新增概念。该公司关联的其它概念板块还包括：医美概念、创新药、肝炎概念。立方制药主营业务：药品制剂及原料药的研发、生产、销售,药品与医疗器械的批发、零售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600039241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2600067531","title":"每周股票复盘：立方制药（003020）拟3400万元转让美沙拉秦肠溶片MAH权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067531","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067531?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:38","pubTimestamp":1767379091,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：立方制药拟以3,400.00万元转让美沙拉秦肠溶片药品上市许可持有人及相关权益。公司公告汇总第六届董事会第三次会议审议通过《关于签署〈药品上市许可持有人转让合同〉的议案》，同意以3,400万元（含税）向葵花药业集团佳木斯鹿灵制药有限公司转让美沙拉秦肠溶片药品上市许可持有人及相关权益，表决结果为同意8票、反对0票、弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2585463389","title":"立方制药（003020）披露2025年中期权益分派实施公告，11月24日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585463389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585463389?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:00","pubTimestamp":1763978459,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，立方制药报收于27.82元，较前一交易日上涨0.54%，最新总市值为52.91亿元。该股当日开盘27.69元，最高27.93元，最低27.52元，成交额达5595.2万元，换手率为1.46%。公司近日发布《2025年中期权益分派实施公告》，宣布以现有总股本190,182,182股为基数，向全体股东每10股派发现金红利2.00元（含税），合计派发现金红利38,036,436.40元（含税）。本次权益分派不送红股，不以资本公积转增股本。股权登记日为2025年11月27日，除权除息日为2025年11月28日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2585148051","title":"立方制药(003020.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148051","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585148051?lang=zh_cn&edition=full","pubTime":"2025-11-21 20:46","pubTimestamp":1763729198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药 发布公告，近日，公司收到国家药品监督管理局下发的达格列净二甲双胍缓释片、达格列净二甲双胍缓释片及达格列净二甲双胍缓释片药品注册上市许可申请《受理通知书》。据悉，达格列净二甲双胍缓释片是一种固定剂量复方制剂，由钠-葡萄糖协同转运蛋白 2抑制剂达格列净和双胍类药物盐酸二甲双胍组成，结合了两种作用机制不同但相互协同作用的降糖药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"立方制药(003020.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2579101458","title":"立方制药（003020）2025年三季报简析：净利润同比增长1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101458","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101458?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:46","pubTimestamp":1761864398,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期立方制药发布2025年三季报。根据财报显示，立方制药净利润同比增长1.65%。截至本报告期末，公司营业总收入10.81亿元，同比下降3.95%，归母净利润1.21亿元，同比上升1.65%。按单季度数据看，第三季度营业总收入3.48亿元，同比下降2.12%，第三季度归母净利润3071.45万元，同比下降26.08%。去年的净利率为10.04%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020"],"gpt_icon":0},{"id":"2579922053","title":"立方制药(003020.SZ)发布前三季度业绩，归母净利润1.21亿元，同比增长1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579922053","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579922053?lang=zh_cn&edition=full","pubTime":"2025-10-29 16:46","pubTimestamp":1761727619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药(003020.SZ)发布2025年三季度报告，前三季度，公司实现营业收入10.81亿元，同比下降3.95%。归属于上市公司股东的净利润1.21亿元，同比增长1.65%。归属于上市公司股东的扣除非经常性损益的净利润8935.46万元，同比下降20.23%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["003020"],"gpt_icon":0},{"id":"2569829713","title":"立方制药：9月22日高管戴天鹤减持股份合计10000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2569829713","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569829713?lang=zh_cn&edition=full","pubTime":"2025-09-23 21:02","pubTimestamp":1758632546,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月23日市场公开信息、上市公司公告及交易所披露数据整理，立方制药（003020）最新董监高及相关人员股份变动情况：2025年9月22日公司高管戴天鹤共减持公司股份1.0万股，占公司总股本为0.0053%。变动期间公司股价下跌0.56%，9月22日当日收盘报28.28元。立方制药近半年内的董监高及核心技术人员增减持详情如下：立方制药的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300034473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2518242523","title":"立方制药(003020.SZ)拟与立方投资签署代为培育协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2518242523","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518242523?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:12","pubTimestamp":1741605164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，立方制药 发布公告，由于药品研发的投资大、周期长、环节多，且易受到不可控因素影响，研发进度及结果、未来产品市场竞争形势均存在不确定性，为降低公司投资风险，有效获取商业机会，同时避免公司控股股东与公司构成同业竞争，最大限度保护公司及全体股东特别是中小股东利益，公司拟与立方投资签署《代为培育协议》，委托立方投资按照市场原则为公司代为培育创新药研究相关项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","003020"],"gpt_icon":0},{"id":"2518253247","title":"立方制药最新公告：聘任季铁城、郑勇为副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2518253247","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518253247?lang=zh_cn&edition=full","pubTime":"2025-03-10 19:11","pubTimestamp":1741605080,"startTime":"0","endTime":"0","summary":"立方制药公告称，公司于2025年3月10日召开董事会，审议通过聘任季铁城、郑勇为公司副总经理，任期自董事会审议通过之日起至第五届董事会届满之日止。季铁城、郑勇符合高级管理人员任职要求，未持有公司股份，与公司控股股东、实际控制人、董事长季俊虬为父子关系，与公司其他董事、监事、高级管理人员及持有公司5%以上股份的股东之间不存在关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000027568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["003020","BK0250"],"gpt_icon":0},{"id":"2516300885","title":"立方制药新提交“立优加”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516300885?lang=zh_cn&edition=full","pubTime":"2025-03-01 06:20","pubTimestamp":1740781249,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日合肥立方制药股份有限公司新提交“立优加”商标注册申请。商标申请详情如下：今年以来合肥立方制药股份有限公司新申请注册商标1件，截止目前公司共持有注册商标174件，另有5件商标尚在注册申请中。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030100010043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","003020"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773884540526,"stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":-0.0381},{"period":"3month","weight":-0.0585},{"period":"6month","weight":-0.1229},{"period":"1year","weight":0.3191},{"period":"ytd","weight":-0.0429}],"compareEarnings":[{"period":"1week","weight":-0.017},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.0481},{"period":"6month","weight":0.0636},{"period":"1year","weight":0.1846},{"period":"ytd","weight":0.0237}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"合肥立方制药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"18105人(较上一季度减少88.68%)","perCapita":"7606股","listingDate":"2020-12-15","address":"安徽省合肥市蜀山区长江西路669号立方厂区","registeredCapital":"19018万元","survey":"　　合肥立方制药股份有限公司的主营业务是医药工业及医药商业。公司的主要产品是心脑血管类、精神麻醉类、消化系统类、眼科类、皮肤外用类、其他类。公司连续八年入选“中国化学制药工业企业综合实力百强”，并先后取得“国家火炬计划重点高新技术企业”“安徽省创新型企业”“中国医药工业最具投资价值企业”“皖美品牌示范企业”“安徽省专精特新冠军企业”“合肥市知识产权示范企业”等荣誉。","listedPrice":23.13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"立方制药,003020,立方制药股票,立方制药股票老虎,立方制药股票老虎国际,立方制药行情,立方制药股票行情,立方制药股价,立方制药股市,立方制药股票价格,立方制药股票交易,立方制药股票购买,立方制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"立方制药(003020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供立方制药(003020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}